Nutra Pharma Corp (NPHC) Asset Writedowns and Impairment (2018 - 2023)

Nutra Pharma has disclosed Asset Writedowns and Impairment across 6 years of filings, most recently posting $105465.0 for Q1 2023.

• In Q1 2023, Asset Writedowns and Impairment changed N/A year-over-year to $105465.0; the TTM figure through Dec 2023 stood at $105465.0 (up 3.27% YoY), while the FY2023 annual figure was $105465.0, up 46.9% from the prior year.
• Asset Writedowns and Impairment came in at $105465.0 for Q1 2023 at Nutra Pharma, up from $71796.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $105465.0 in Q1 2023 to a low of -$108197.0 in Q4 2020.
• Average Asset Writedowns and Impairment over 5 years is $18140.2, with a median of $26064.5 recorded in 2021.
• The largest YoY upside for Asset Writedowns and Impairment was 1316.28% in 2020 against a maximum downside of 615.22% in 2020.
• Over 5 years, Asset Writedowns and Impairment stood at $21000.0 in 2019, then slumped by 615.22% to -$108197.0 in 2020, then soared by 128.03% to $30330.0 in 2021, then surged by 136.72% to $71796.0 in 2022, then soared by 46.9% to $105465.0 in 2023.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $105465.0 in Q1 2023, $71796.0 in Q4 2022, and -$21799.0 in Q3 2022.